“Sloppy” Searle Studies Described By FDA At Kennedy Hearing; Rauscher “Outraged”
In Brief: Override Failure Would Leave Cancer Program With No Money or New Projects Of Any Kind
NCI Budget for FY 1977 Would Halt New Research
Congressman Obey Attacks NCI for Not Supporting Basic Research
Nutrition RFPs Will Really Be Grants, Gori Says
Cyclamate Committee Finds No Proof Of Carcinogenicity
Trending Stories
- Brawley: ACS prostate cancer screening guideline should say no to “mass screening”
- NCI’s Letai, FDA’s Diamantas identify strategies to speed up cancer trials
Letai: 150 days to start a cancer trial is too long—cancer centers need to accept a little risk - ACS strengthens recommendation for prostate cancer screening
Many will hear the endorsement and ignore the limitations - Kay “Taddy” Dickersin, NBCC co-founder, dies at 74
- CMS rule cuts overall oncology payments by estimated 2%
Final rule slashes 340B, moves toward site-neutrality - Is it time to re-assess the practice and practicality of screening colonoscopy?
Modeling data, ACS guideline support greater use of noninvasive tests to ease system strain, help save lives









